| 379 | 0 | 37 |
| 下载次数 | 被引频次 | 阅读次数 |
血管重塑是心血管疾病的关键病理过程，人参皂苷作为人参的主要活性成分，具有多靶点协同作用，可通过抑制氧化应激和炎症反应、调控多条关键信号通路，有效改善血管内皮功能障碍、抑制血管平滑肌细胞的增殖与迁移，并维持细胞外基质的稳态，在抗血管重塑方面展现出显著潜力，这些研究成果为人参皂苷的临床应用奠定了坚实的药理学基础。然而，因其复杂的吸收机制、较低的生物利用度及多样的代谢途径，人参皂苷的药动学研究仍面临诸多挑战。未来研究需进一步探索其药动学特性与新型药物递送系统的优化和创新，并加强开展临床试验验证其疗效，以期为人参皂苷的临床应用提供更精准的指导，为患者提供更有效的治疗方案。
Abstract：Vascular remodeling is a key pathological process in cardiovascular diseases. Ginsenosides, as the main active components of ginseng, exert synergistic multi-target effects by inhibiting oxidative stress and inflammatory responses, regulating multiple key signaling pathways, effectively improving vascular endothelial dysfunction, suppressing the proliferation and migration of vascular smooth muscle cells, and maintaining the homeostasis of the extracellular matrix. These findings demonstrate the significant potential of ginsenosides in combating vascular remodeling and lay a solid pharmacological foundation for their clinical application. However, the pharmacokinetic study of ginsenosides still face numerous challenges due to their complex absorption mechanisms, low bioavailability, and diverse metabolic pathways. Future research should further explore their pharmacokinetic characteristics, optimize novel drug delivery systems, and strengthen clinical trials to validate their efficacy. This will provide more precise guidance for the clinical application of ginsenosides and offer more effective treatment options for patients.
[1]BENJAMIN EJ, BLAHA MJ, CHIUVE SE, et al. Heart disease and stroke statistics-2017 update:a report from the American Heart Association[J]. Circulation, 2017, 135(10):e146-e603.
[2]GRAY MP, FATKIN D, INGLES J, et al. Genetic testing in cardiovascular disease[J]. Med J Aust, 2024, 220(8):428-434.
[3]OUARNE M, PENA A, FRANCO CA. From remodeling to quiescence:the transformation of the vascular network[J]. Cells Dev, 2021, 168(12):203735.
[4]ZHU GX, ZUO JL, XU L, et al. Ginsenosides in vascular remodeling:cellular and molecular mechanisms of their therapeutic action[J]. Pharmacol Res, 2021, 169:105647.
[5]YU W, CAI S, ZHAO J, et al. Beyond genome:advanced omics progress of Panax ginseng[J]. Plant Sci, 2024, 341:112022.
[6]LI J, ZHAO J, WANG X, et al. Ginsenoside—a promising natural active ingredient with steroidal hormone activity[J]. Food Funct,2024, 15(4):1825-1839.
[7]MANCUSO C. Panax notoginseng:pharmacological aspects and toxicological issues[J]. Nutrients, 2024, 16(13):2120.
[8]LEE CH, KIM JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases[J]. J Ginseng Res,2014, 38(3):161-166.
[9]KIM JH. Pharmacological and medical applications of Panax ginseng and ginsenosides:a review for use in cardiovascular diseases[J]. J Ginseng Res, 2018, 42(3):264-269.
[10]RATAN ZA, HAIDERE MF, HONG YH, et al. Pharmacological potential of ginseng and its major component ginsenosides[J]. J Ginseng Res, 2021, 45(2):199-210.
[11]HOU M, WANG R, ZHAO S, et al. Ginsenosides in Panax genus and their biosynthesis[J]. Acta Pharm Sin B, 2021, 11(7):1813-1834.
[12]ZHANG L, GAO X, YANG C, et al. Structural characters and pharmacological activity of protopanaxadiol-type saponins and protopanaxatriol-type saponins from ginseng[J]. Adv Pharmacol Pharm Sci, 2024, 2024:9096774.
[13]SHI ZY, ZENG JZ, WONG A. Chemical structures and pharmacological profiles of ginseng saponins[J]. Molecules,2019, 24(13):2443.
[14]LEUNG KW, WONG AS. Pharmacology of ginsenosides:a literature review[J]. Chin Med, 2010, 5:20.
[15]LIU Y, ZHANG H, DAI X, et al. A comprehensive review on the phytochemistry, pharmacokinetics, and antidiabetic effect of ginseng[J]. Phytomedicine, 2021, 92(12):153717.
[16]ZHAO J, SU C, YANG C, et al. Determination of ginsenosides Rb1, Rb2, and Rb3 in rat plasma by a rapid and sensitive liquid chromatography tandem mass spectrometry method:application in a pharmacokinetic study[J]. J Pharm Biomed Anal, 2012, 64-65:94-97.
[17]MENDEZ-BARBERO N, GUTIERREZ-MUNOZ C, BLANCOCOLIO LM. Cellular crosstalk between endothelial and smooth muscle cells in vascular wall remodeling[J]. Int J Mol Sci, 2021,22(14):7284.
[18]BUDATHA M, ZHANG J, SCHWARTZ MA. Fibronectin-mediated inflammatory signaling through integrin alpha5 in vascular remodeling[J]. J Am Heart Assoc, 2021, 10(17):e021160.
[19]SOROKIN V, VICKNESON K, KOFIDIS T, et al. Role of vascular smooth muscle cell plasticity and interactions in vessel wall inflammation[J]. Front Immunol, 2020, 11:599415.
[20]CAI Z, GONG Z, LI Z, et al. Vascular extracellular matrix remodeling and hypertension[J]. Antioxid Redox Signal, 2021,34(10):765-783.
[21]YAMAMURA A, NAYEEM MJ, SATO M. Roles of growth factors on vascular remodeling in pulmonary hypertension[J]. Nihon Yakurigaku Zasshi, 2021, 156(3):161-165.
[22]YE C, ZHENG F, WU N, et al. Extracellular vesicles in vascular remodeling[J]. Acta Pharmacol Sin, 2022, 43(9):2191-2201.
[23]YANG F, YANG MY, LE JQ, et al. Protective effects and therapeutics of ginsenosides for improving endothelial dysfunction:from therapeutic potentials, pharmaceutical developments to clinical trials[J]. Am J Chin Med, 2022, 50(3):749-772.
[24]DAIBER A, STEVEN S, WEBER A, et al. Targeting vascular(endothelial)dysfunction[J]. Br J Pharmacol, 2017, 174(12):1591-1619.
[25]ZHANG Q, LIU J, DUAN H, et al. Activation of Nrf2/HO-1signaling:an important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress[J]. J Adv Res, 2021, 34:43-63.
[26]GENG J, FU W, YU X, et al. Ginsenoside Rg3 alleviates ox-LDL induced endothelial dysfunction and prevents atherosclerosis in Apo E-/-mice by regulating PPARgamma/FAK signaling pathway[J].Front Pharmacol, 2020, 11:500.
[27]NAGAR H, CHOI S, JUNG SB, et al. Rg3-enriched Korean red ginseng enhances blood pressure stability in spontaneously hypertensive rats[J]. Integr Med Res, 2016, 5(3):223-229.
[28]ZHOU P, LU S, LUO Y, et al. Attenuation of TNF-alpha-induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-kappaB, JNK and p38 signaling pathways[J].Front Pharmacol, 2017, 8:464.
[29]SUN JL, ABD EA, JEONG JH, et al. Ginsenoside Rb2 ameliorates LPS-induced inflammation and ER stress in HUVECs and THP-1Cells via the AMPK-mediated pathway[J]. Am J Chin Med,2020, 48(4):967-985.
[30]PARK DH, PARK JY, SHIN M, et al. Wound healing effect of 20(S)-protopanaxadiol of ginseng involves VEGF-ERK pathways in HUVECs and diabetic mice[J]. Processes, 2023, 11(3):692.
[31]WANG J, HE X, LV S. Notoginsenoside-R1 ameliorates palmitic acid-induced insulin resistance and oxidative stress in HUVEC via Nrf2/ARE pathway[J]. Food Sci Nutr, 2023, 11(12):7791-7802.
[32]XU S, ILYAS I, LITTLE PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond:from mechanism to pharmacotherapies[J]. Pharmacol Rev, 2021, 73(3):924-967.
[33]LOBUE A, HEUSER SK, LINDEMANN M, et al. Red blood cell endothelial nitric oxide synthase:a major player in regulating cardiovascular health[J]. Br J Pharmacol, 2023. doi:10.1111/bph.16230.
[34]PAN C, HUO Y, AN X, et al. Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation[J]. Vascul Pharmacol, 2012, 56(3-4):150-158.
[35]CHEN C, JIANG J, LU JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells[J]. Am J Physiol Heart Circ Physiol, 2010, 299(1):H193-H201.
[36]LU JM, JIANG J, JAMALUDDIN MS, et al. Ginsenoside Rb1blocks ritonavir-induced oxidative stress and eNOS downregulation through activation of estrogen receptor-beta and upregulation of SOD in human endothelial cells[J]. Int J Mol Sci, 2019, 20(2):294.
[37]LAN TH, XU ZW, WANG Z, et al. Ginsenoside Rb1 prevents homocysteine-induced endothelial dysfunction via PI3K/Akt activation and PKC inhibition[J]. Biochem Pharmacol, 2011, 82(2):148-155.
[38]HIEN TT, KIM ND, POKHAREL YR, et al. Ginsenoside Rg3increases nitric oxide production via increases in phosphorylation and expression of endothelial nitric oxide synthase:essential roles of estrogen receptor-dependent PI3-kinase and AMP-activated protein kinase[J]. Toxicol Appl Pharmacol, 2010, 246(3):171-183.
[39]KWOK HH, GUO GL, LAU JK, et al. Stereoisomers ginsenosides-20(S)-Rg(3)and-20(R)-Rg(3)differentially induce angiogenesis through peroxisome proliferator-activated receptorgamma[J]. Biochem Pharmacol, 2012, 83(7):893-902.
[40]GAO Y, GAO CY, ZHU P, et al. Ginsenoside Re inhibits vascular neointimal hyperplasia in balloon-injured carotid arteries through activating the eNOS/NO/cGMP pathway in rats[J]. Biomed Pharmacother, 2018, 106:1091-1097.
[41]高晨盈,王俊逸,罗云梅,等.人参皂苷Re对球囊损伤所致大鼠血管内膜增生及NF-κB p65信号通路的影响[J].中国病理生理杂志, 2016, 32(7):1246-1251.
[42]ZHANG J, LV W, LIU X, et al. Ginsenoside Rh4 prevents endothelial dysfunction as a novel AMPK activator[J]. Br J Pharmacol, 2024, 181(18):3346-3363.
[43]LIN CP, LI W. Pharmacokinetic effect of Astragalus membranaceus and Panax notoginseng saponins on arginine absorption and nitric oxide production in healthy subjects[J]. Func Foods Health Dis,2023, 13(6):307-319.
[44]JOVANOVSKI E, PEEVA V, SIEVENPIPER JL, et al. Modulation of endothelial function by Korean red ginseng(Panax ginseng C.A.Meyer)and its components in healthy individuals:a randomized controlled trial[J]. Cardiovasc Ther, 2014, 32(4):163-169.
[45]ZUREK M, AAVIK E, MALLICK R, et al. Epigenetic regulation of vascular smooth muscle cell phenotype switching in atherosclerotic artery remodeling:a mini-review[J]. Front Genet, 2021, 12:719456.
[46]WANG Z. Regulation of cell cycle progression by growth factorinduced cell signaling[J]. Cells, 2021, 10(12):3227.
[47]UZBEKOV R, PRIGENT C. A journey through time on the discovery of cell cycle regulation[J]. Cells, 2022, 11(4):704.
[48]LI QY, CHEN L, FU WH, et al. Ginsenoside Rb1 inhibits proliferation and inflammatory responses in rat aortic smooth muscle cells[J]. J Agric Food Chem, 2011, 59(11):6312-6318.
[49]WANG T, YU XF, QU SC, et al. Ginsenoside Rb3 inhibits angiotensinⅡ-induced vascular smooth muscle cells proliferation[J]. Basic Clin Pharmacol Toxicol, 2010, 107(2):685-689.
[50]HUANG J, LI LS, YANG DL, et al. Inhibitory effect of ginsenoside Rg1 on vascular smooth muscle cell proliferation induced by PDGF-BB is involved in nitric oxide formation[J]. Evid Based Complement Alternat Med, 2012, 2012:314395.
[51]HOU L, ZOU Z, WANG Y, et al. Exploring the anti-atherosclerosis mechanism of ginsenoside Rb1 by integrating network pharmacology and experimental verification[J]. Aging(Albany NY), 2024,16(8):6745-6756.
[52]GAO Y, ZHU P, XU SF, et al. Ginsenoside Re inhibits PDGF-BBinduced VSMC proliferation via the e NOS/NO/c GMP pathway[J].Biomed Pharmacother, 2019, 115(6):108934.
[53]LI SG, YAN MZ, ZHANG D, et al. Effects of ginsenoside Rg1 on the senescence of vascular smooth muscle cells[J]. Genet Mol Res, 2016, 15(3):15038434.
[54]LU W, LIN Y, HAIDER N, et al. Ginsenoside Rb1 protects human vascular smooth muscle cells against resistin-induced oxidative stress and dysfunction[J]. Front Cardiovasc Med, 2023, 10:1164547.
[55]HUYNH D, JIN Y, van NGUYEN D, et al. Ginsenoside Rh1 inhibits angiotensinⅡ-induced vascular smooth muscle cell migration and proliferation through suppression of the ROS-Mediated ERK1/2/p90RSK/KLF4 signaling pathway[J]. Antioxidants(Basel),2022, 11(4):643.
[56]XUE Q, YU T, WANG Z, et al. Protective effect and mechanism of ginsenoside Rg2 on atherosclerosis[J]. J Ginseng Res, 2023, 47(2):237-245.
[57]HUANG Y, CUI L, YANG H, et al. Lysozyme improves the inhibitory effects of panax notoginseng saponins on phenotype transformation of vascular smooth muscle cells by binding to ginsenoside Re[J]. Front Nutr, 2021, 8:795888.
[58]GUO M, GUO G, XIAO J, et al. Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis[J]. J Cell Mol Med, 2018,22(6):3202-3214.
[59]LEE JY, LIM KM, KIM SY, et al. Vascular smooth muscle dysfunction and remodeling induced by ginsenoside Rg3, a bioactive component of ginseng[J]. Toxicol Sci, 2010, 117(2):505-514.
[60]LI C, WANG Z, LI G, et al. Acute and repeated dose 26-week oral toxicity study of 20(S)-ginsenoside Rg3 in Kunming mice and Sprague-Dawley rats[J]. J Ginseng Res, 2020, 44(2):222-228.
[61]MAJESKY MW, WEISER-EVANS M. The adventitia in arterial development, remodeling, and hypertension[J]. Biochem Pharmacol, 2022, 205:115259.
[62]LIU M, LOPEZ DJAB, CHENG K. Cardiac fibrosis:myofibroblastmediated pathological regulation and drug delivery strategies[J].Adv Drug Deliv Rev, 2021, 173:504-519.
[63]ZHANG L, CHEN Y, LI G, et al. TGF-beta1/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts[J]. Lipids Health Dis, 2016, 15:2.
[64]高晨盈,王俊逸,罗云梅,等.人参皂苷Re对球囊损伤大鼠血管内膜增殖及TGF-β1/Smads信号通路的影响[J].中草药,2017, 48(1):143-148.
[65]WANG M, CHEN X, JIN W, et al. Ginsenoside Rb3 exerts protective properties against cigarette smoke extract-induced cell injury by inhibiting the p38 MAPK/NF-kappaB and TGF-beta1/VEGF pathways in fibroblasts and epithelial cells[J]. Biomed Pharmacother, 2018, 108(12):1751-1758.
[66]FU Y, ZHOU Y, WANG K, et al. Extracellular matrix interactome in modulating vascular homeostasis and remodeling[J]. Circ Res, 2024, 134(7):931-949.
[67]SINGH D, RAI V, AGRAWAL DK. Regulation of collagen and collagen in tissue injury and regeneration[J]. Cardiol Cardiovasc Med, 2023, 7(1):5-16.
[68]ZHANG XJ, HE C, TIAN K, et al. Ginsenoside Rb1 attenuates angiotensin-induced abdominal aortic aneurysm through inactivation of the JNK and p38 signaling pathways[J]. Vascul Pharmacol, 2015, 73:86-95.
[69]YANG YH, GU XP, HU H, et al. Ginsenoside Rg1 inhibits nucleus pulposus cell apoptosis, inflammation and extracellular matrix degradation via the YAP1/TAZ pathway in rats with intervertebral disc degeneration[J]. J Orthop Surg Res, 2022, 17(1):555.
[70]PARK JD. Metabolism and drug interactions of Korean ginseng based on the pharmacokinetic properties of ginsenosides:Current status and future perspectives[J]. J Ginseng Res, 2024, 48(3):253-265.
[71]ZHANG HY, NIU W, OLALEYE OE, et al. Comparison of intramuscular and intravenous pharmacokinetics of ginsenosides in humans after dosing Xueshuantong, a lyophilized extract of Panax notoginseng roots[J]. J Ethnopharmacol, 2020, 253:112658.
[72]LIU C, HU M, GUO H, et al. Combined contribution of increased intestinal permeability and inhibited deglycosylation of ginsenoside Rb1 in the intestinal tract to the enhancement of ginsenoside Rb1exposure in diabetic rats after oral administration[J]. Drug Metab Dispos, 2015, 43(11):1702-1710.
[73]KIM HJ, OH TK, KIM YH, et al. Pharmacokinetics of ginsenoside Rb1, Rg3, Rk1, Rg5, F2, and compound K from red ginseng extract in healthy Korean volunteers[J]. Evid Based Complement Alternat Med, 2022, 2022:8427519.
[74]WANG Y, WU J, HONG Y, et al. Ginsenosides retard atherogenesis via remodelling host-microbiome metabolic homeostasis[J]. Br J Pharmacol, 2024, 181(12):1768-1792.
[75]CHEN Y, ZHANG KX, LIU H, et al. Impact of ginsenoside Rb1 on gut microbiome and associated changes in pharmacokinetics in rats[J]. Sci Rep, 2024, 14(1):21168.
[76]SHARMA A, LEE HJ. Ginsenoside compound K:insights into recent studies on pharmacokinetics and health-promoting activities[J]. Biomolecules, 2020, 10(7):1028.
[77]SANA SS, CHANDEL A, RAORANE CJ, et al. Recent advances in nano and micro formulations of Ginsenoside to enhance their therapeutic efficacy[J]. Phytomedicine, 2024, 134:156007.
[78]ZHAO L, WANG L, CHANG L, et al. Ginsenoside CK-loaded selfnanomicellizing solid dispersion with enhanced solubility and oral bioavailability[J]. Pharm Dev Technol, 2020, 25(9):1127-1138.
[79]HAO F, HE Y, SUN Y, et al. Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate[J]. Saudi J Biol Sci, 2016, 23(1):S113-S125.
[80]KIM MH, KIM KT, SOHN SY, et al. Formulation and evaluation of nanostructured lipid carriers(NLCs)of 20(S)-protopanaxadiol(PPD)by box-behnken design[J]. Int J Nanomedicine, 2019,14:8509-8520.
[81]GONG F, WANG Z, MO R, et al. Nano-sponge-like liposomes remove cholesterol crystals for antiatherosclerosis[J]. J Control Release, 2022, 349:940-953.
[82]MA Y, ZHAO Y, LUO M, et al. Advancements and challenges in pharmacokinetic and pharmacodynamic research on the traditional Chinese medicine saponins:a comprehensive review[J]. Front Pharmacol, 2024, 15:1393409.
基本信息:
DOI：10.14109/j.cnki.xyylc.2025.12.04
中图分类号:R285
引用信息:
[1]黄嫚,罗琪,高杨.人参皂苷在血管重塑中的研究进展[J].中国新药与临床杂志,2025,44(12):899-907.DOI:10.14109/j.cnki.xyylc.2025.12.04.
基金信息:
贵州省卫生健康委科学技术基金项目（gzwkj2023-519）; 遵义市科技计划项目(遵市科合HZ字（2022）416号)
2026-01-08
2026-01-08
2026-01-08